血清脑源性神经营养因子(BDNF)浓度预测多发性骨髓瘤患者周围神经病变及总生存
研究纳入91例接受硼替佐米和/或沙利度胺方案化疗的新诊断多发性骨髓瘤患者,采用酶联免疫吸附试验检测血清脑源性神经营养因子(BDNF)。BDNF浓度与周围神经病变严重程度相关(P=0.0463),对化疗诱导的周围神经病变(CIPN)诊断具有显著价值(敏感度76%、特异度71.43%,曲线下面积0.77,95%CI 0.64-0.88,P<0.0001)。低BDNF是与总生存(OS)缩短相关的独立不良预后因素(HR=2.79,P=0.0470)。
要点
- BDNF浓度与多发性骨髓瘤患者周围神经病变严重程度相关(P=0.0463)。
- BDNF诊断CIPN的敏感度76%、特异度71.43%,AUC=0.77(95%CI 0.64-0.88),P<0.0001。
- 低BDNF是与OS缩短相关的独立不良预后因素(HR=2.79,P=0.0470)。
核心结论
- BDNF水平可能具有预后作用,并可作为预测多发性骨髓瘤患者CIPN的有用生物标志物。
研究设计与样本
- 研究组由91例接受硼替佐米和/或沙利度胺方案化疗的新诊断多发性骨髓瘤患者组成。
- 采用酶联免疫吸附试验(ELISA)检测血清BDNF,按CTCAE第5版标准评估周围神经病变。
主要发现
- BDNF浓度与周围神经病变严重程度相关(P=0.0463)。
- 治疗有应答的患者BDNF值更高(P=0.0326)。
- BDNF预测8个周期治疗后无应答的敏感度为100%、特异度为61.5%(P=0.0142)。
- BDNF诊断CIPN的敏感度为76%、特异度为71.43%,AUC=0.77(95%CI 0.64-0.88),P<0.0001。
- 低BDNF是与总生存(OS)缩短相关的独立不良预后因素(HR=2.79,P=0.0470)。
关键数值与推荐
- BDNF预测8个周期治疗后无应答:敏感度100%、特异度61.5%,P=0.0142。
- BDNF诊断CIPN:敏感度76%、特异度71.43%,AUC=0.77(95%CI 0.64-0.88),P<0.0001。
- 低BDNF与OS缩短相关:HR=2.79,P=0.0470。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Brain-derived neurotrophic factor (BDNF) is a protein with a potent influence on several aspects of neuronal and blood vessel functions. However, its prognostic potential and functional role in multiple myeloma (MM) remain largely unknown. In this study, we investigated the influence of BDNF on the risk of chemotherapy-induced peripheral neuropathy (CIPN) and clinical outcome. Study group consisted of 91 newly-diagnosed MM patients treated with bortezomib and/or thalidomide-based chemotherapy. Detection of BDNF in serum was performed using ELISA. Polyneuropathy was assessed according to the CTCAE Criteria v5. We observed that BDNF concentration correlated with the severity of polyneuropathy (P = 0·0463). Higher BDNF values were noted in patients who responded to treatment (P = 0·0326), and BDNF proved to be a useful marker to predict lack of response after eight cycles of treatment (sensitivity - 100%, specificity - 61·5%, P = 0·0142). Moreover this marker showed significant diagnostic usefulness in diagnosis of CIPN (sensitivity - 76%, specificity - 71·43%; area under the curve (AUC)= 0·77, 95%, confidence interval (CI): 0·64-0·88; P < 0·0001). Low BDNF was an independent, unfavourable prognostic factor associated with reduced overall survival (OS) (hazard ratio (HR) = 2·79, P = 0·0470). In conclusion, BDNF level may play a prognostic role and constitute a useful biomarker in predicting CIPN in MM patients.
引用
- Szudy-Szczyrek A, Mlak R, Bury-Kamińska M, et al. Serum brain-derived neurotrophic factor (BDNF) concentration predicts polyneuropathy and overall survival in multiple myeloma patients. Br J Haematol. 2020. PMID: 32567687. doi:10.1111/bjh.16862
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。